- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20:46 | Parabilis Medicines' Quest to Drug the Undruggable Picks Up $745M From Upsized IPO | 2 | MedCity News | ||
| 19:36 | Regeneron-backed Parabilis surges after record-setting IPO | 3 | Seeking Alpha | ||
| 17:46 | Parabilis sets a record with a $670M biotech IPO | 1 | BioPharma Dive | ||
| 16:46 | Parabilis Medicines sets biotech record with $670m IPO | 4 | Pharmaceutical Technology | ||
| 14:31 | Cancer biotech Parabilis Medicines prices upsized IPO at $20, above the range | 1 | Renaissance Capital | ||
| 12:26 | Cancer-focused Parabilis' upsized $670M IPO breaks new for record for biotechs | 2 | FierceBiotech | ||
| 11:58 | Cancer biotech Parabilis books record IPO, raising $670m | 1 | pharmaphorum | ||
| PARABILIS MEDICINES Aktie jetzt für 0€ handeln | |||||
| 09:42 | Parabilis Medicines prices upsized IPO at $20 per share | 2 | Seeking Alpha | ||
| 08:54 | Parabilis Medicines prices upsized IPO at $19 per share | 2 | Seeking Alpha | ||
| 02:30 | Parabilis Medicines, Inc.: Parabilis Medicines Announces Pricing of Upsized Initial Public Offering | 101 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines, Inc. (Nasdaq: PBLS) ("Parabilis"), a clinical-stage biopharmaceutical company built to develop transformative medicines addressing... ► Artikel lesen | |
| 02:30 | Parabilis Medicines prices $670M IPO at $20 per share | 1 | Investing.com | ||
| Di | Parabilis Medicines: Börsengang dürfte Preisspanne übertreffen - Bloomberg | 2 | Investing.com Deutsch | ||
| Di | Parabilis upsizes IPO seeking to raise more than $600M | 1 | Seeking Alpha | ||
| Di | Cancer biotech Parabilis ups IPO plans to potentially record-setting $637M | 1 | FierceBiotech | ||
| Di | Cancer biotech Parabilis Medicines ups shares offered by 33% ahead of $600 million IPO | 2 | Renaissance Capital | ||
| Fr | Parabilis Medicines, Inc. - 8-A12B, Registration of securities | 1 | SEC Filings | ||
| Fr | Parabilis eyes $475m IPO to push lead asset into Phase III | 1 | Pharmaceutical Technology | ||
| Fr | Parabilis prices IPO at an ambitious $475 million | 1 | pharmaphorum | ||
| Do | Parabilis preps $413M IPO to fuel desmoid tumor drug into phase 3 | 3 | FierceBiotech | ||
| Do | Regeneron backed Parabilis seeks up to $476M in U.S. IPO | 10 | Seeking Alpha |
1 2 3 Weiter >>
41 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 32,265 | +1,65 % | QIAGEN NV zündet Turbo - jetzt nicht den Einstieg verpassen! | ||
| TANGO THERAPEUTICS | 28,690 | -9,09 % | Starke Studiendaten: Nach 626% Kursplus in einem Jahr: Dieser Krebsspezialist macht Anleger sprachlos | © Foto: Bernd Weißbrod/dpa Ein Wirkstoff gegen die tödlichste Form von Bauchspeicheldrüsenkrebs zeigt Daten, die selbst erfahrene Onkologen aufhorchen lassen. Die Aktie reagierte entsprechend.Pankreas-Karzinom... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 13,030 | -8,82 % | Summit Therapeutics files for $500M common stock offering; shares slide over 9% | ||
| BIONTECH | 74,80 | -0,20 % | Rendite-Chance Krebsmarkt: Mit BioNTech, Vidac Pharma und Pfizer den nächsten Mrd.-Trigger erwischen | Die Alterung der Gesellschaft lässt die Gesundheitsausgaben rasant steigen. Im Krebssegment zeichnet sich ein Billionenmarkt ab, denn bis 2040 werden jährlich über 30 Mio. Neuerkrankungen erwartet.... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 82,72 | -2,68 % | RBC Capital raises Apogee Therapeutics stock price target to $97 | ||
| ADMA BIOLOGICS | 8,480 | +4,43 % | Kehoe Law Firm, P.C.: ADMA Biologics Stock Alert (ADMA) - Kehoe Law Firm, P.C. Investigating Potential Securities Claims on Behalf of ADMA Biologics Investors | Philadelphia, Pennsylvania--(Newsfile Corp. - May 7, 2026) - Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,035 | -5,75 % | Recursion Pharmaceuticals: Recursion Reports First Quarter Financial Results and Provides Business Update | Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and predictable... ► Artikel lesen | |
| ABSCI | 6,365 | -6,81 % | Top Biotech Gainers: VERU Teams Up With NVO, ABSI On Watch, ALVO Resubmits BLAs To FDA... | REYKJAVIK (dpa-AFX) - Thursday's top gainers include Veru, following a Novo Nordisk collaboration; Health Catalyst, following a divestment of its revenue workflow and analytics software business... ► Artikel lesen | |
| IMMUNOVANT | 31,210 | -1,27 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 | IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA)... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 240,66 | -3,86 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Vormatrigine Program Update | POWER1 Study in highly refractory patients with focal onset seizures did not meet its primary success measure Secondary measure, the 50% response rate, was met and seizure reduction during the second... ► Artikel lesen | |
| ERASCA | 13,370 | -0,30 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| AMGEN | 293,80 | -1,59 % | EQS-News: Amgen: Europäische Kommission erteilt Zulassung für Imdylltra von Amgen für die Behandlung von kleinzelligem Lungenkrebs im fortgeschrittenen Stadium | EQS-News: Amgen
/ Schlagwort(e): Sonstiges/Sonstiges
EUROPÄISCHE KOMMISSION ERTEILT ZULASSUNG FÜR IMDYLLTRA VON AMGEN FÜR DIE BEHANDLUNG VON KLEINZELLIGEM... ► Artikel lesen | |
| BEAM THERAPEUTICS | 29,485 | -3,23 % | Beam Therapeutics Inc. - 8-K, Current Report | ||
| CG ONCOLOGY | 54,92 | -3,09 % | CG Oncology, Inc. - 8-K, Current Report | ||
| HARMONY BIOSCIENCES | 35,480 | +4,05 % | H.C. Wainwright reiterates Harmony Biosciences stock rating at buy |
PARABILIS MEDICINES INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 31,850 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PARABILIS MEDICINES INC finden Sie auf Wallstreet Online.